Since establishment in 2018, our network has forged close partnerships with the NHS and industry to deliver advanced therapies to patients.

With funding from NIHR, the ATTC network aims to build upon its existing work, expand its reach, and integrate its initiatives into standard practice. This will be delivered through a series of interconnected initiatives, detailed below, each addressing persistent barriers in the field.

  • Clinical Trials Acceleration
  • Streamlining processes and implementing innovative methodologies to expedite the progression of ATMP clinical trials.

  • Training and Education
  • Developing specialised training programs to equip researchers and healthcare professionals with the necessary skills and knowledge to navigate the complexities of ATMP trials.

  • Patient and Public Involvement and Engagement
  • Engaging with the patient and public communities to foster understanding, awareness, and involvement in ATMP clinical trials.

    Patient and Public Involvement and Engagement
  • Patient Recruitment
  • Implementing strategies to improve patient access and recruitment for ATMP trials, ensuring diverse and representative participation.

  • Data Collection and Use
  • Enhancing data infrastructure and analytics capabilities to optimise decision-making and drive evidence-based advancements in ATMP research.

  • Logistics
  • Enhancing logistical capabilities to streamline the supply chain and ensure seamless coordination of ATMP trial activities.

The UK is a world leader in clinical research with 187 active advanced therapy trials, and with 9.5% of global ATMP trials having representation in the UK1. However, many more products are in development; further action is needed to ensure that the NHS can deliver advanced therapies to patients at scale across the UK and that the UK maintains its position as a globally attractive location for clinical research.

1 CGT Catapult ATMP Clinical Trials Database